title: Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support.
abstract: BACKGROUND
  Castleman's disease or angiofollicular lymph node hyperplasia is a rare entity with a localized/unicentric or a generalized/multicentric presentation. While surgery is curable for most localized presentations, there is limited information regarding the optimal management of the multicentric type. The latter type is associated with a poor prognoses and can be associated with the development of lymphoma and infections.
  
  
  METHODS
  In this report we describe a case of multicentric Castleman's disease who failed steroids and chemotherapy and developed a follicular mixed lymphoma. He was treated with high-dose chemotherapy with autologous stem-cell support and remains disease at four years of follow-up.
  
  
  CONCLUSIONS
  A long-term durable remission may be possible with high dose chemotherapy with stem-cell support. This treatment modality should be considered an option in the management of multicentric Castleman's disease.
authors.affiliation: Stanford University School of Medicine, Division of Oncology, CA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Advani
authors.forename: R
authors.initials: R
authors.lastname: Warnke
authors.forename: S
authors.initials: S
authors.lastname: Rosenberg
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005871:Castleman Disease / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D011379:Prognosis; D016896:Treatment Outcome